Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects

Trial Profile

Ascending Single Dose Study of the Safety, Tolerability, and Pharmacokinetics of PAZ 417 Administered Orally to Healthy Young Japanese Male and Healthy Elderly Japanese Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Jan 2010

At a glance

  • Drugs Aleplasinin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 28 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 18 Jun 2008 New trial record.
    • 28 Jan 2008 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top